+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Tissue factor and tissue factor pathway inhibitor: a potential role in pregnancy and obstetric vascular complications?

Tissue factor and tissue factor pathway inhibitor: a potential role in pregnancy and obstetric vascular complications?

Clinica Chimica Acta; International Journal of Clinical Chemistry 372(1-2): 43-46

Tissue factor (TF) is the principal cellular initiator of normal blood coagulation. As a result it is considered to be a major regulator of haemostasis and thrombogenesis. In vivo TF activity is regulated by specific circulating inhibitor known as "tissue factor pathway inhibitor (TFPI)". TF is also essential for other cellular processes including embryogenesis and angiogenesis as well as in implantation where it is particularly important in the first trimester. TF is highly expressed in syncytiotrophoblasts (STB) while TFPI is expressed in human umbilical vein endothelial cells (HUVEC). TFPI may be internalized via an endocytic pathway and recycled to the cell surface. The procoagulant tendency of STB may reflect a physiological need for immediate inhibition of hemorrhage in the placental intervillous spaces. Furthermore, the haemostatic balance involving STB and HUVEC may be critical for normal placental function and pregnancy outcome. Homozygous knockouts of both TF and TFPI are generally lethal in fetal mice; heterozygotes survive but with altered coagulation parameters. Despite their apparent association with placental microcirculation-thrombi-formation only few studies have addressed the role of TF and TFPI in the pathogenesis of gestational vascular complications. In this context, detailed studies could provide clinically relevant information.

(PDF emailed within 0-6 h: $19.90)

Accession: 012696125

Download citation: RISBibTeXText

PMID: 16713593

DOI: 10.1016/j.cca.2006.03.025

Related references

Microparticles bearing tissue factor and tissue factor pathway inhibitor in gestational vascular complications. Journal of Thrombosis and Haemostasis 7(6): 1047-1050, 2009

The role of tissue factor and tissue factor pathway inhibitor in blood coagulation and in thrombotic complications. Kardiologia Polska 68(10): 1158-1162, 2011

Increased risk of gestational vascular complications in women with low free tissue factor pathway inhibitor plasma levels out of pregnancy. Thrombosis and Haemostasis 105(1): 66-71, 2011

The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: the transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor. Thrombosis and Haemostasis 77(3): 492-497, 1997

Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor-A in carotid atherosclerotic plaques. European Journal of Vascular and Endovascular Surgery 30(1): 41-47, 2005

Importance of tissue factor residues A165A166 for the accelerated inhibition of factor VIIa Tissue factor by tissue factor pathway inhibitor in the presence of factor Xa. Circulation 90(4 PART 2): I617, 1994

Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thrombosis and Haemostasis 73(5): 873-875, 1995

Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor. European Journal of Biochemistry 270(12): 2576-2582, June, 2003

Tissue factor pathway inhibitor and a direct factor Xa inhibitor but not a glycoprotein IIb/IIIa inhibitor antagonize platelet activation induced by factor Xa and tissue factor. Blood 90(10 SUPPL 1 PART 2): 69B, Nov 15, 1997

Expression of Tissue Factor and Tissue Factor Pathway Inhibitor by Vascular Endothelium: Effects of Shear Stress and Endothelial Cell Origin. Journal of Vascular and Interventional Radiology 10(7): 983-985, 1999

Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition. Journal of Biological Chemistry 274(40): 28225-28232, 1999

Oncostatin M induces procoagulant activity in human vascular smooth muscle cells by modulating the balance between tissue factor and tissue factor pathway inhibitor. Blood Coagulation & Fibrinolysis 13(5): 449-455, 2002

Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 99(10): 3602-3612, 2002

Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor VIIa with Xa tissue factor pathway inhibitor. Biochemistry (American Chemical Society) 34: 867-71, 1995

Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology 93(1-2): 31-36, 2000